Statutory Instruments

MISUSE OF DRUGS ACT 1977 (CONTROLLED DRUGS) (DECLARATION) ORDER 2017 S.I. No. 531 of 2017

The purpose of this Order is to declare certain substances, products and preparations to be controlled drugs for the purposes of the Misuse of Drugs Acts 1977 to 2016. The drugs concerned are— 3,4-dichloro-N-(2-dimethylamino-cyclohexyl)-N-methyl-benzamide (otherwise known as U-47700); Ethyl phenyl(piperidin-2-yl)acetate (otherwise known as Ethylphenidate); [1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (otherwise known as XLR-11); and N-methyl-1-(thiophen-2-yl)propan-2-amine (otherwise known as Methiopropamine).

Misuse of Drugs (Supervision of Prescription and Supply of Methadone and Medicinal Products containing Buprenorphine authorised for Opioid Substitution Treatment) Regulations 2017 SI No. 522 of 2017

These Regulations replace the Misuse of Drugs (Supervision of Prescription and Supply of Methadone) Regulations 1998 (S.I. No 225 of 1998). The Regulations add certain buprenorphine medicinal products authorised for opioid substitution treatment to the Schedule of products which fall within the scope of these Regulations. These Regulations also update a number of references and

Consultative Council on Hepatitis C (Membership) Order 2017 SI No. 510 of 2017

This Order amends the Consultative Council on Hepatitis C (Establishment) Order 1996 and has the effect of inserting a general descriptive term for women who contracted Hepatitis C through the administration of Anti-D in the State and provides for two representatives of this group to be Members of the council. SI No. 510 of 2017

Page 2/79